Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.

Abstract Categories


  • 1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)
  • 1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)
  • 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 
  • 1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)
  • 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (all aspects)
  • 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1i. Basic and applied virology (incl in vitro and in vivo models, novel methods)
  • 2a. Tuberculosis and other mycobacterial infections (incl antimycobacterial drugs, treatment & susceptibility/resistance, diagnostics & epidemiology)
  • 2b. Severe sepsis, bacteraemia & endocarditis (incl host bio-markers and outcome prediction)
  • 2c. Community-acquired respiratory infections
  • 2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections
  • 2e. Community acquired skin, soft tissue, bone & joint (excl prostheses)
  • 2f. Community acquired nervous system and other multi-system bacterial infections 
  • 2g. Zoonotic bacterial diseases (incl foodborne and waterborne pathogens and One Health aspects, excl AMR)
  • 2h. Other intracellular or rare bacteria
  • 3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives
  • 3b. Resistance surveillance & epidemiology: Gram-negatives
  • 3c. Susceptibility testing methods (incl assay validation and comparative studies, excl TB)
  • 3d. Resistance mechanisms incl in vitro and in vivo studies, mobile elements (excl TB)
  • 3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)
  • 3f. Clinical outcome of resistant infections (excl trials of new drugs)
  • 3g. Spread of resistance incl reservoirs, ecology, models (excl nosocomial transmission)
  • 3h. Policy aspects of AMR incl societal impact, economics, mitigation
  • 4a. Diagnostic bacteriology – culture based and general microbiology
  • 4b. Lab management (incl automation, information, QC/QA)
  • 4c. MALTI-TOF and other proteomic methods
  • 4d. Molecular diagnostics (incl POCT and syndromic testing)
  • 4e. Strain typing and surveillance (methods other than genomics)
  • 4f. Whole genome sequencing (diagnostic, typing)
  • 4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)
  • 4h. Clinical metagenomics
  • 4i. Bioinformatics tools & pipelines
  • 4j. Other novel diagnostic technologies
  • 5a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents
  • 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring
  • 5c. New or repurposed antibacterial agents: clinical trials
  • 5d. Antimicrobial stewardship and improved prescribing  (incl interventions, decision-support / prediction tools, behavioural aspects)
  • 5e. Safety and adverse effects of treatment
  • 5f. Pharmacoepidemiology / pharmacoeconomics (incl cost-effectiveness, modelling)
  • 6a. Fungal disease epidemiology
  • 6b. Diagnostic mycology (incl molecular)
  • 6c. Antifungal drugs & treatment (incl clinical trials)
  • 6d. Antifungal resistance & susceptibility testing (incl surveillance)
  • 6e. Basic mycology (incl in vitro and in vivo studies, pathogenesis)
  • 7a. Diagnostic parasitology
  • 7b. Antiparasitic susceptibility & resistance
  • 7c. Antiparasitic drugs & treatment
  • 7d. Parasitic disease epidemiology
  • 7e. Travel medicine & migrant health
  • 7f. Food & water safety and environmental health
  • 7g. Global health, public health
  • 7h. Infections in low-resource settings
  • 8a. Intravascular catheter-related infections
  • 8b. Other foreign-body and implant infections
  • 8c. Surgical site infections
  • 8d. Healthcare-associated pneumonia (incl VAP)
  • 8e. Hospital epidemiology, transmission, surveillance & screening (incl. environment)
  • 8f. Other healthcare associated infections (incl CDI)
  • 8g. Infection control interventions and trials (incl. microbiota transplantation)
  • 8h. Disinfection & biocides
  • 8i. Healthcare workers and infection prevention (incl vaccination, behavior and practices)
  • 9a. Microbial pathogenesis & virulence
  • 9b. Host-pathogen interaction (including basic microbiome studies)
  • 9c. Preclinical biofilm studies
  • 9d. Experimental and cellular microbiology
  • 9e. Basic studies using Omics (in vitro and in vivo) 
  • 10a. Host genetics: infection susceptibility & immunodeficiency
  • 10b. Clinical epidemiology and treatment of infections in immunocompromised hosts
  • 10c. General vaccinology (incl. policy, social aspects)
  • 10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses)
  • 10e. Antibacterial vaccines
  • 10f. Immune response to infection (excl sepsis biomarkers)
  • 10g. Laboratory assessment of immunity and immune resposne to infection
  • 11a. Professional affairs and career development
  • 11b. Publishing, ethics, other academic affairs
  • 11c. Medical education for CM/ID
  • 11d. Digital health and infection (incl AI, data mining, informatics)
  • 11e. Diversity and equality
  • 11f. Advocacy and role of patients 
  • 12a. Basic science and virology
  • 12b. Epidemiology- local, regional, global
  • 12c. Clinical features, case management, outcome (incl long-term)
  • 12d. Diagnostics (incl molecular, genomic, rapid tests)
  • 12e. Drug development and treatment modalities (incl. clinical trials)
  • 12f. Immune response (incl immunity assessment, immunomodulation)
  • 12g. Vaccine development, trials, efficacy, policy
  • 12h. Infection control incl healthcare facilities, community settings
  • 12i. Public health policy, mitigation (non-pharmaceutical interventions)
  • 12j. Preparedness and response (COVID and future pandemics)
  • 12k. Other societal aspects (incl. economics)
  • 12l. Virus evolution, variants and impact 
  • 21. New drugs
  • 22. Clinical trials
  • 23. COVID-19
  • 24. Outbreaks and public health emergencies other than COVID-19
  • 25. Other